Battling the JN.1 Surge: Unveiling strategies to shield against the next wave of COVID with homoeopathy

Abstract

This article delves into the emergence of the JN.1 sub-variant of the Omicron strain, labelled a "variant of interest" by the World Health Organization. Originating from BA.2.86, JN.1 carries the spike protein L455S mutation, raising concerns about its potential to evade vaccine immunity. With a global prevalence of 27.1%, impacting nations like India, Canada, France, Singapore, Sweden, and the UK, JN.1's increased transmissibility and immune evasion potential are highlighted. In India, JN.1 contributes to a surge in cases, notably with lower hospitalization rates. The article explores JN.1's pathophysiology, emphasizing the ACE2 receptor binding impact of the S: L455S mutation. Clinical features from mild to severe cases are detailed, and investigative methods, including genomic sequencing and serological assays, are crucial for understanding and managing JN.1. Despite vaccine resistance, current immunization remains effective against severe outcomes. The article concludes by discussing homoeopathic management, stressing a holistic symptom relief approach, and underscores the importance of collaborative efforts, transparency, and ongoing research to mitigate JN.1's impact and protect global public health.